

BIOCON BIOLOGICS GLOBAL PLC
BALANCE SHEET AS AT MARCH 31, 2025

(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2025</u>
ASSETS		
Non-current assets		
Financial assets		
(i) Loan and advances	4	7,92,328
Total non-current assets		7,92,328
Current assets		
Financial assets		
(i) Trade receivables	1	3,021
(ii) Cash and cash equivalents	2	84
(iii) Other financial assets	3	28,045
Total current assets		31,150
TOTAL		8,23,478
EQUITY AND LIABILITIES		
Equity		
Equity share capital	5	134
Other equity	6	1,088
Total equity		1,222
Non-current liabilities		
Financial liabilities		
(i) Borrowings	8	7,83,465
Total non-current liabilities		7,83,465
Current liabilities		
Financial liabilities		
(i) Trade payables	7	13,000
(ii) Other financial liabilities	9	25,791
Total current liabilities		38,791
TOTAL		8,23,478

BIOCON BIOLOGICS GLOBAL PLC**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD 19 JULY 2024 to MARCH 31, 2025**

(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended March 31, 2025</u>
Income		
Revenue from operations	10	43,881
Other income	11	30,039
Total revenue		<u>73,920</u>
Expenses		
Purchase of traded goods	12	43,021
Other expenses	13	60
Finance cost	14	29,388
Total expenses		<u>72,469</u>
Profit before tax		<u>1,451</u>
Tax expense		
Current tax		363
Deferred Tax		-
Tax expense		<u>363</u>
Profit for the year		<u><u>1,088</u></u>

BIOCON BIOLOGICS GLOBAL PLC
STATEMENT OF CASH FLOW FOR THE PERIOD ENDED MARCH 31, 2025
(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2025
I Cash flows from operating activities	
Profit after tax	1,088
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Interest expense	29,388
Interest income	(30,047)
Tax expense	363
Operating profit before working capital changes	792
Movements in working capital	
Increase) in trade receivables	(3,021)
(Increase) in loans and advances and other assets	(28,045)
Increase in trade payable, other liabilities and provisions	38,428
Cash generated from operations	8,154
Direct taxes paid	-
Net cash flow generated from operating activities	8,154
II Cash flows from investing activities	
Loan advanced to Susidiary	(7,92,328)
Interest received	30,047
Net cash flow (used in) investing activities	(7,62,281)
III Cash flows from financing activities	
Proceeds from Senior Secured Loan	7,83,465
Interest paid	(29,388)
Proceeds from issue of equity shares	134
Net cash flow generated from financing activities	7,54,211
IV Net increasein cash and cash equivalents (I + II + III)	84
V Cash and cash equivalents at the beginning of the year	-
VI Cash and cash equivalents at the end of the year (IV + V)	84
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	84
Total cash and cash equivalents [refer note 2]	84

BIOCON BIOLOGICS GLOBAL PLC**Notes to financial statements for the period ended March 31, 2025****(All amounts in US Dollars Thousands, except share data and unless otherwise stated)**

	March 31, 2025
1. Trade receivables	
Other Receivables	
Outstanding for a period less than six months from the date they are due for payment	
(a)Unsecured, considered good	3,021
	<u>3,021</u>
Allowance for credit loss	-
	<u>3,021</u>
2. Cash and cash equivalents	
Balances with banks:	
On current accounts	84
	<u>84</u>
3. Other financial assets	
Current	
VAT Receivables	1
Interest Accrued on loan to related party	28,044
	<u>28,045</u>
4. Loan and advances	
Loans to related parties	7,92,328
	<u>7,92,328</u>
5. Share capital	
Authorised	
Issued, subscribed and fully paid-up	
100,000 Equity shares of GBP 1 each	134
Total issued, subscribed and fully paid-up share capital	<u>134</u>
6. Other equity	
Surplus in the statement of profit and loss	
Profit for the year	1,088
Net surplus in the statement of profit and loss	<u>1,088</u>
7. Trade payables	<u>13,000</u>
8. Borrowings	
Non-current borrowings	
Senior Secured Notes	7,83,465
	<u>7,83,465</u>
9. Other financial liabilities	
Interest accrued but not due	25,791
	<u>25,791</u>

BIOCON BIOLOGICS GLOBAL PLC

Notes to financial statements for the period ended March 31, 2025

(All amounts in US Dollars Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2025
<hr/>	
10. Revenue from operations	
Sale of Products	
Traded goods	43,021
Support service cross charge to Group Companies	860
	<u>43,881</u>
<hr/>	
11. Other income	
Foreign exchange fluctuations, net	(8)
Interest income on loan	30,047
	<u>30,039</u>
<hr/>	
12. Purchase of traded goods	43,021
	<u>43,021</u>
<hr/>	
13. Other expenses	
Legal and professional fees	39
Miscellaneous expenses	1
Director's fees	20
	<u>60</u>
<hr/>	
14. Finance cost	
Interest on Senior Secured Notes	29,388
	<u>29,388</u>
<hr/>	